NEW YORK, Oct. 18, 2022 /PRNewswire/ -- 5WPR, one of the largest independently-owned PR firms in the U.S., announces today the expansion of their mental health group offerings with a specialty sub-division focused on the use of psychedelic therapies.
The division works with industry leaders focusing on the use of ketamine treatments to assist in mental health diagnoses including depression, anxiety, and post-traumatic stress disorders. With these treatments becoming more mainstream, the team looks forward to helping educate consumers about the benefits, and directing them to the best treatment centers and resources.
"Year-round, 5WPR works alongside our clients to break down stigmas surrounding mental health, and the treatment of mental health, including the use of psychedelic therapies," said 5WPR CEO, Dara A. Busch. "October is Depression Awareness Month, and we feel this is an appropriate time to shine a light on the groundbreaking work the mental health group has been executing."
PR services offered to mental health and psychedelic therapy clients include strategic media relations and thought leadership opportunities, messaging and positioning around new and existing treatment offerings, new office openings and expansion announcement support.
5W Public Relations is a full-service PR agency in NYC known for cutting-edge programs that engage with businesses, issues and ideas. With more than 300 professionals serving clients in B2C (Beauty & Fashion, Consumer Brands, Entertainment, Food & Beverage, Health & Wellness, Travel & Hospitality, Technology, Nonprofit), B2B (Corporate Communications and Reputation Management), Public Affairs, Crisis Communications and Digital Marketing (Social Media, Influencer, Paid Media, SEO). 5W was named to Inc. Magazine's Best Workplaces 2022 list, awarded 2020 PR Agency of The Year, and brings leading businesses a resourceful, bold and results-driven approach to communication.
Dara A. Busch
email@example.com / 212.999.5585
SOURCE 5W Public Relations
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.